On the afternoon of Wednesday, January 21, Geron Corp.'s president and CEO Thomas Okarma received a phone call from the US Food and Drug Administration, notifying
him that Geron's 21,000-odd page investigational new drug (IND) application for the first-ever Phase 1 human trial of a medical treatment derived from human embryonic stem cells had been linkurl:approved.;http://www.the-scientist.com/blog/display/55353/ The decision, which lifted a hold on the trial in place since May of 2008, has been greeted by linkurl:enthusiasm;http://www.the-scientist.com/blog/display/55354/ from industry and patient advocates.Okarma spoke with __The Scientist__ today (January 26) about the decision, rumors over the political timing of the announcement, and when the much-anticipated trial is set to begin. __**The Scientist**__: How does it feel to finally be entering the clinic with a stem-cell treatment for spinal cord injuries?__**Thomas Okarma**__: It is probably my greatest professional accomplishment. It is something that I and the people that I work with have been...
Image: Julie Jacobson, Associated Press

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?